Biomaterial Database

Use of a revised version of the psychotropic medication efficacy graph. 1994

J Jordan

Northeast Care Center, North Royalton, OH 44133.

A medication efficacy graph developed by Spirrison and Grosskopf (1991) was revised and applied in a case study to effectively monitor a client's progress. The revision combined several aspects of client behavior into one graph that could aid clinicians in assessing a client under psychiatric care. Revised applications of the graph should also enable clinicians to measure and display not just incidents of maladaptive behaviors but weighted maladaptive behaviors, adaptive behaviors, potency of medication, and side effects, all of which provide a better overall picture of the client's behavior.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008607	Intellectual Disability	Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)	Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D010554	Personality Disorders	A major deviation from normal patterns of behavior.	Avoidant Personality Disorder,Impulse-Ridden Personality,Inadequate Personality,Avoidant Personality Disorders,Impulse Ridden Personality,Personality Disorder,Personality Disorder, Avoidant,Personality Disorders, Avoidant,Personality, Impulse-Ridden,Personality, Inadequate
D006220	Haloperidol	A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)	Haldol
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000525	Alprazolam	A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)	Alprazolan,Alprox,Apo-Alpraz,Cassadan,D-65MT,Esparon,Kalma,Novo-Alprazol,Nu-Alpraz,Ralozam,Tafil,Trankimazin,U-31,889,Xanax,Apo Alpraz,D65MT,Novo Alprazol,Nu Alpraz,U31,889
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019965	Neurocognitive Disorders	Diagnoses of DEMENTIA and AMNESTIC DISORDER are subsumed here. (DSM-5)	Clerambault Syndrome,Delirium, Dementia, Amnestic, Cognitive Disorders,Kandinsky Syndrome,Mental Disorders, Organic,Organic Brain Syndrome, Nonpsychotic,Organic Mental Disorders,Organic Mental Disorders, Psychotic,Psychoses, Traumatic,Mild Neurocognitive Disorder,Nonpsychotic Organic Brain Syndrome,Disorder, Mild Neurocognitive,Disorder, Neurocognitive,Disorders, Mild Neurocognitive,Disorders, Neurocognitive,Disorders, Organic Mental,Mental Disorder, Organic,Mild Neurocognitive Disorders,Neurocognitive Disorder,Neurocognitive Disorder, Mild,Neurocognitive Disorders, Mild,Organic Mental Disorder,Traumatic Psychoses